Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ruxolitinib

ruxolitinib

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ruxolitinib

58 trials tracked of ruxolitinib: 12 in phase 3 or 4 and 6 with published results. The most-cited published study has 490 citations.

58Trials tracked
12Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 3 12 Phase 2 45 Phase 1 1
  1. Phase 3 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Completed · 490 cited
  2. Phase 3 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Completed · 252 cited
  3. Phase 3 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Completed · 48 cited
  4. Phase 3 Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm Completed · 47 cited
  5. Phase 3 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) Completed · 11 cited
  6. Phase 3 Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo Completed · 4 cited
Show 44 more trials
  1. Phase 3 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed
  2. Phase 3 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. Completed
  3. Phase 3 Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis Completed
  4. Phase 3 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed
  5. Phase 3 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed
  6. Phase 3 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed
  7. Phase 2 LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma Completed
  8. Phase 2 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF Completed
  9. Phase 2 Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Completed
  10. Phase 2 Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis Completed
  11. Phase 2 Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed
  12. Phase 2 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis Completed
  13. Phase 2 Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant Completed
  14. Phase 2 Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Completed
  15. Phase 2 Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients Completed
  16. Phase 2 A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) Completed
  17. Phase 2 Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata Completed
  18. Phase 2 Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis Completed
  19. Phase 2 Topical Ruxolitinib in Chronic Hand Dermatitis Completed
  20. Phase 2 A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Completed
  21. Phase 2 Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca Completed
  22. Phase 2 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed
  23. Phase 2 Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) Completed
  24. Phase 2 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Completed
  25. Phase 2 Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica Completed
  26. Phase 2 Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia Completed
  27. Phase 2 Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Completed
  28. Phase 2 Ruxolitinib and Lenalidomide for Patients With Myelofibrosis Completed
  29. Phase 2 Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. Completed
  30. Phase 2 Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. Completed
  31. Phase 2 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed
  32. Phase 2 Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease Completed
  33. Phase 2 Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus Completed
  34. Phase 2 JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Completed
  35. Phase 2 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) Completed
  36. Phase 2 A Phase 2 Study of RO7490677 In Participants With Myelofibrosis Completed
  37. Phase 2 Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults Completed
  38. Phase 2 Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Completed
  39. Phase 2 A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Completed
  40. Phase 2 Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids Completed
  41. Phase 2 A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis Completed
  42. Phase 2 Study of Ruxolitinib in Pancreatic Cancer Patients Completed
  43. Phase 2 Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Completed
  44. Phase 2 Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Completed

Showing the 50 most-cited and recently-updated of 58 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome
Pediatrics Sys. Review
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome Two children with severe arthritis found relief using a new drug approach
This narrative review synthesizes a retrospective case series and literature search on ruxolitinib for systemic juvenile idiopathic arthriti…
Two children with severe arthritis complications found relief using a new drug approach, offering hope for those who struggle with standard …
Frontiers May 28, 2026
Narrative review proposes phenotype-driven framework for managing myelofibrosis splenomegaly
Cardiology Sys. Review
Narrative review proposes phenotype-driven framework for managing myelofibrosis splenomegaly New combo strategies shrink spleens better than older treatments for myelofibrosis
This narrative review addresses the management of splenomegaly in patients with myelofibrosis. The authors synthesize evidence regarding eme…
Emerging combination strategies like pelabresib plus ruxolitinib or navitoclax plus ruxolitinib show superior spleen shrinkage for myelofibr…
Frontiers May 26, 2026
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis
Allergy & Immunology Sys. Review
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis A single patient found relief from blood cancer with a new drug combo
This case report and literature review describes a 52-year-old male with connective tissue disease, chronic myelomonocytic leukemia, and mye…
One man with blood cancer saw his fever and anemia improve after two years on a specific drug mix, offering a glimpse into potential new tre…
Frontiers May 14, 2026
Ruxolitinib plus photopheresis shows promise for steroid-refractory chronic graft-versus-host disease
Allergy & Immunology Cohort
Ruxolitinib plus photopheresis shows promise for steroid-refractory chronic graft-versus-host disease New Hope for Stubborn Transplant Complication
A retrospective analysis compared ruxolitinib plus extracorporeal photopheresis versus photopheresis alone in patients with steroid-refracto…
This combo may help patients reduce or stop steroid use — a major win for quality of life.
Frontiers Apr 22, 2026
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months
Psychiatry Cohort
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months A Rheumatoid Arthritis Drug May Help Save Lungs in Crisis
This retrospective observational case series examined six consecutive patients hospitalized for acute exacerbation of rheumatoid arthritis–a…
A small study suggests a familiar arthritis pill may help calm sudden, dangerous lung flare-ups in people with rheumatoid arthritis.
Frontiers Apr 16, 2026
Review explores JAK inhibitor combination with PD-1 blockade for overcoming immunotherapy resistance
Oncology Sys. Review
Review explores JAK inhibitor combination with PD-1 blockade for overcoming immunotherapy resistance Review explores combining JAK inhibitors with immunotherapy for resistant cancers
A systematic review discusses the rationale for combining JAK inhibitors with PD-1 blockade immunotherapy based on emerging preclinical and …
Blocking inflammation around tumors with JAK inhibitors may help immune drugs work better for cancers that have stopped responding to standa…
Frontiers Apr 3, 2026
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results
Oncology Phase III
Phase 3 trial of navitoclax plus ruxolitinib versus ruxolitinib alone in myelofibrosis posts results Phase 3 trial tests navitoclax with ruxolitinib for myelofibrosis spleen volume
A phase 3 randomized controlled trial in 252 adults with myelofibrosis compared navitoclax plus ruxolitinib to ruxolitinib plus placebo.
A new drug combination aims to shrink painful enlarged spleens in myelofibrosis patients, but results from this large global trial are not y…
CT.gov Apr 2, 2026